Want to see MAZE full AI Analyst Report?
MAZE Stock Chart & Stats
$27.68
$1.05(3.79%)
At close: 4:00 PM EDT
$27.68
$1.05(3.79%)
Day’s Range― - ―
52-Week Range$12.81 - $53.65
Previous CloseN/A
Volume102.86K
Average Volume (3M)698.25K
Market Cap
$1.51B
Enterprise Value$1.41K
Total Cash (Recent Filing)$411.09M
Total Debt (Recent Filing)$21.46M
Price to Earnings (P/E)―
Beta0.98
Next Earnings
Nov 05, 2026EPS Estimate
-0.76Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.74
Shares Outstanding55,345,260
10 Day Avg. Volume397,036
30 Day Avg. Volume698,254
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.02
Price to Sales (P/S)0.00
P/FCF Ratio-15.79
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$66.25Price Target Upside139.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.73
Revenue Forecast (FY)$22.00M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Large Equity CushionSustained low debt relative to equity provides structural financial flexibility for a development-stage biotech. A large equity cushion reduces near-term solvency risk, supports multi-year R&D spending and clinical programs, and lessens reliance on high-cost borrowing during execution.
$150M Financing Extends Runway Into 2029A material financing that extends runway into 2029 meaningfully lowers the probability of imminent dilution or halted development. With funded operations across multiple quarters, management can advance clinical milestones and licensing discussions without repeated near-term capital raises, improving strategic optionality.
Board And Audit Continuity After Annual MeetingRe-election of directors and auditor ratification provide stable governance and audit oversight during critical development and financing phases. Continuity at the board and audit level supports consistent strategic oversight and investor confidence across multi-year clinical and regulatory programs.
Bears Say
Heavy Ongoing Cash BurnSustained negative operating and free cash flow indicates the business is structurally cash consuming and dependent on external capital to fund R&D. Over multiple quarters this erodes flexibility, raises dilution risk, and forces prioritization of programs if future financing conditions tighten.
Large Net Losses And Volatile RevenueMaterial net losses and wide swings in reported revenue underscore that core revenue generation and margins are not yet durable. Episodic revenue in prior periods appears non-recurring, complicating forecasting and making long-term margin sustainability and commercial viability uncertain until repeatable revenue streams emerge.
Finance Leadership Consolidation After SVP ResignationConsolidating accounting and finance under the CFO can streamline execution but concentrates responsibility during a sensitive period of financing execution and clinical spend. Leadership transitions increase operational and reporting risk, and could slow financial controls or capital planning if not smoothly executed.
Maze Therapeutics, Inc. News
MAZE FAQ
What was Maze Therapeutics, Inc.’s price range in the past 12 months?
Maze Therapeutics, Inc. lowest stock price was $12.81 and its highest was $53.65 in the past 12 months.
What is Maze Therapeutics, Inc.’s market cap?
Maze Therapeutics, Inc.’s market cap is $1.51B.
When is Maze Therapeutics, Inc.’s upcoming earnings report date?
Maze Therapeutics, Inc.’s upcoming earnings report date is Nov 05, 2026 which is in 84 days.
How were Maze Therapeutics, Inc.’s earnings last quarter?
Maze Therapeutics, Inc. released its earnings results on Aug 11, 2026. The company reported -$0.76 earnings per share for the quarter, missing the consensus estimate of -$0.717 by -$0.043.
Is Maze Therapeutics, Inc. overvalued?
According to Wall Street analysts Maze Therapeutics, Inc.’s price is currently Undervalued.
Does Maze Therapeutics, Inc. pay dividends?
Maze Therapeutics, Inc. does not currently pay dividends.
What is Maze Therapeutics, Inc.’s EPS estimate?
Maze Therapeutics, Inc.’s EPS estimate is -0.76.
How many shares outstanding does Maze Therapeutics, Inc. have?
Maze Therapeutics, Inc. has 55,345,260 shares outstanding.
What happened to Maze Therapeutics, Inc.’s price movement after its last earnings report?
Maze Therapeutics, Inc. reported an EPS of -$0.76 in its last earnings report, missing expectations of -$0.717. Following the earnings report the stock price went up 0.806%.
Which hedge fund is a major shareholder of Maze Therapeutics, Inc.?
Currently, no hedge funds are holding shares in MAZE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Maze Therapeutics, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$66.25 (139.34% Upside)
$66.25 (139.34% Upside)
Blogger Sentiment
Bullish
MAZE Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 214.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.2%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
70.57%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
26.10%
Trailing 12-Months
Company Description
Maze Therapeutics, Inc.
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease. The company also develops MZE001, an investigational oral small molecule inhibitor of muscle-specific glycogen synthase clinical program for the treatment of Pompe disease. It has a license agreement with Trace Neuroscience, Inc. to discovery research program targets UNC13A; the Shionogi & Co., Ltd to research, develop, manufacture, and commercialize MZE001; and Neurocrine Biosciences, Inc. to discover research program that targets ATXN2. The company was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
MAZE Stock 12 Month Forecast
Average Price Target
$66.25
▲(139.34% Upside)
Technical Analysis
Intellia Therapeutics
―
Damora Therapeutics
―
Recursion Pharmaceuticals
―
Ginkgo Bioworks Holdings
―
Generate Biomedicines, Inc.
―
Ownership Overview
11.02% Insiders
5.52% Mutual Funds
13.03% Other Institutional Investors
61.57% Public Companies and
Individual Investors